In June 2022, the highest level of support for the use of COVID vaccine mandates for international travel was reported among people surveyed in India at 96.3 percent. On the other hand, the lowest level of support for the use of such a mandate was reported in South Africa at 46.6 percent. This statistic illustrates the level of support for using COVID vaccine mandate for international travel in 2022, by country.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The annual pre-kindergarten (pre-K) through 12th grade school immunization survey collects school-level, grade-specific data on vaccine coverage and exemptions. The survey collects vaccination and exemption status data on children who entered the school system on or before a specified date during the fall semester. Individual vaccine information on each student is not collected. This table shows the vaccination exemptions (medical and religious) and percentage vaccinated and compliant for each school-entry mandated vaccine series reported by school year, county, and grade. Percentage of students vaccinated is the number of students with the required number of doses of a given vaccine divided by the total number of students. Data for each grade includes all schools who reported with that given grade level. School-mandated vaccine series for students enrolled in kindergarten are inactivated polio, DTaP (diphtheria, tetanus, and acellular pertussis), MMR (measles, mumps, and rubella), hepatitis B, varicella and hepatitis A. Additional mandated vaccines for students enrolled in 7th grade include meningococcal conjugate vaccine (MCV) and Tdap (tetanus, diphtheria, and acellular pertussis). Influenza vaccine is a requirement for pre-K students only, who are 24 through 59 months of age. Each child has 1 of 4 possible vaccination statutes: Vaccinated, Exempt (Religious), Exempt (Medical) or Non-compliant. The criteria shown below are used to assess whether a child is considered vaccinated. • Flu = at least 1 dose of annual influenza vaccine (pre-K only). This is a school entry requirement only for pre-K students 24 through 59 months of age. • Polio = at least 3 doses of inactivated polio vaccine, with the last dose on or after their 4th birthday. This is a school entry requirement starting in kindergarten. • DTaP = at least 4 doses of DTaP vaccine, with the last dose on or after their 4th birthday. This is a school entry requirement starting in kindergarten. • MMR = at least 2 doses of MMR vaccine separated by at least 28 days, with the 1st dose on or after their 1st birthday. This is a school entry requirement starting in kindergarten. • HepB = at least 3 doses of hepatitis B vaccine, with the last dose on or after 24 weeks of age. This is a school entry requirement starting in kindergarten. • Varicella = at least 2 doses of varicella vaccine separated by at least 28 days, with the 1st dose on or after their 1st birthday, or a reliable history of chickenpox disease. This is a school entry requirement starting in kindergarten. • HepA = at least 2 doses of hepatitis A vaccine, given a minimum of six calendar months apart, with the 1st dose on or after their 1st birthday. This is a school entry requirement starting in kindergarten. Starting with the 2019-2020 school year the annual survey included data collection on hepatitis A vaccine for 7th grade students. • MCV = at least 1 dose of meningococcal conjugate vaccine. This is a school entry requirement starting in 7th grade. • Tdap = at least 1 dose of Tdap vaccine. This is a school entry requirement starting in 7th grade. • All = Percentage of students with all above vaccine series required for that grade level. Children without a record of vaccination, but with serologic proof of immunity to certain diseases (measles, mumps, rubella, hepatitis B, hepatitis A, and varicella), meet school entry requirements and may be counted as vaccinated. Data Limitations and Considerations: • The school level data shown here are as tabulated and reported by schools and discrepancies may exist. • The Immunization Program identifies outliers and internally inconsistent data points and works with schools to resolve any data quality issues, when possible. • CT DPH cannot verify the accuracy of vaccine data for individual children or whether the documentation necessary to claim an exemption has been submitted. • Data are collected at the beginning of the school year, by which time vaccines are due.

Context

Data is collected daily from Our World in Data GitHub repository for covid-19, merged and uploaded.

Content

The data contains the following information: * **Country **- this is the country for which the vaccination information is provided;
* Country ISO Code - ISO code for the country;
* **Date **- date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total;
* Total number of vaccinations - this is the absolute number of total immunizations in the country;
* Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people;
* Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme;
* Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country;
* Daily vaccinations - for a certain data entry, the number of vaccination for that date/country;
* Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country;
* Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country;
* Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country;
* Number of vaccinations per day - number of daily vaccination for that day and country;
* Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country;
* Vaccines used in the country - total number of vaccines used in the country (up to date);
* Source name - source of the information (national authority, international organization, local organization etc.);
* Source website - website of the source of information;

Acknowledgements

I would like to specify that I am only making available Our World in Data collected data about vaccinations to Kagglers. My contribution is very small, just daily collection, merge and upload of the updated version, as maintained by Our World in Data in their GitHub repository.

Inspiration

Track COVID-19 vaccination in the World, answer instantly to your questions:
- Which country is using what vaccine?
- In which country the vaccination programme is more advanced?
- Where are vaccinated more people per day? But in terms of percent from entire population ?

Travelers Vaccination Market Outlook

The global travelers vaccination market size was valued at USD 7.8 billion in 2023 and is expected to reach USD 14.9 billion by 2032, growing at a CAGR of 7.2% during the forecast period. One of the primary growth factors driving this market is the increasing awareness among travelers about the health risks associated with international travel and the preventive measures that can be taken to mitigate these risks. The growing incidences of infectious diseases in various parts of the world have led to a rise in demand for travel-specific vaccines. Additionally, government initiatives and international guidelines promoting travel vaccinations contribute significantly to market growth.

The rising number of international travelers is a significant factor propelling the growth of the travelers vaccination market. With globalization and the increase in business and leisure travel, more people are exposed to different health risks that are prevalent in different regions. This has led to an increased emphasis on the need for pre-travel consultations and vaccinations to prevent the spread of infectious diseases. The increased connectivity and ease of travel have also made it imperative for travelers to be well-informed about potential health risks and the necessary vaccinations required to mitigate these risks.

Another key growth factor is the advancements in vaccine development technology. The biopharmaceutical industry has made significant strides in developing vaccines that are more effective and have fewer side effects. Innovations in vaccine delivery methods, such as single-dose vaccines and combination vaccines that protect against multiple diseases, have also made it more convenient for travelers to get vaccinated. These advancements have increased the overall acceptance and uptake of travel vaccines, further driving market growth.

Government regulations and international health organizations play a crucial role in the growth of the travelers vaccination market. Many countries have made certain vaccinations mandatory for travelers entering their borders. For instance, the yellow fever vaccine is required for travelers visiting certain countries in Africa and South America. The World Health Organization and the Centers for Disease Control and Prevention also issue guidelines and recommendations for travelers, which include advice on necessary vaccinations. These regulatory requirements and recommendations ensure a steady demand for travel vaccines.

The adult vaccine segment plays a crucial role in the travelers vaccination market, as adults represent a significant portion of international travelers. With the increasing number of adults traveling for business, leisure, and educational purposes, the demand for adult vaccines has seen a notable rise. These vaccines are essential for protecting adult travelers from various infectious diseases that may be prevalent in their destinations. The adult vaccine market is driven by the need for comprehensive protection against diseases such as hepatitis, typhoid, and yellow fever, which are common concerns for travelers. Additionally, the development of new vaccines targeting specific adult health risks further enhances the market's growth potential. As more adults become aware of the importance of vaccinations in safeguarding their health during travel, the adult vaccine segment is expected to witness sustained growth in the coming years.

From a regional perspective, the travelers vaccination market is witnessing significant growth in regions such as Asia Pacific and North America. The Asia Pacific region, in particular, is expected to see a high growth rate due to the increasing number of outbound travelers from countries like China and India. Additionally, the region's susceptibility to various infectious diseases makes travel vaccinations a critical health measure. In North America, the high disposable income and awareness among travelers about health risks contribute to the strong demand for travel vaccines. Europe also holds a substantial market share due to its well-established healthcare infrastructure and the high number of international travelers.

Vaccine Type Analysis

The travelers vaccination market can be segmented by vaccine type, which includes Hepatitis A, Hepatitis B, Typhoid, Yellow Fever, Rabies, Japanese Encephalitis, Meningococcal, and Others. Hepatitis A and B vaccines are among the most commonly administered travel vaccines due to the widespre

These data contain counts of vaccine preventable disease cases among California residents by county, disease, and year.

The California Department of Public Health (CDPH) maintains a mandatory, passive reporting system for a list(1) of communicable disease cases and outbreaks. The CDPH Immunization Branch conducts surveillance for vaccine preventable diseases. Health care providers and laboratories are mandated to report cases or suspected cases of these communicable diseases to their local health department (LHD). LHDs are also mandated to report these cases to CDPH.

Materials and Methods

Case data sources and inclusion criteria

Data were extracted on communicable disease cases with an estimated onset or diagnosis date from 2001 through the last year indicated, from California Confidential Morbidity Reports and/or Laboratory Reports that were submitted to CDPH and which met the surveillance case definition for that disease.(2) Because of inherent delays in case reporting and depending on the length of follow-up of clinical, laboratory and epidemiologic investigation, cases with eligible onset dates may be added or rescinded after the date of this report.

Definitions

In general, we defined a case as laboratory and/or clinical evidence of infection or disease in a person that satisfied the communicable disease surveillance case definition published by the United States (US) Centers for Disease Control and Prevention (CDC) or by the Council of State and Territorial Epidemiologists (CSTE) at the time the case was reported.

Limitations

Completeness of reporting

The numbers of disease cases in this report are likely to underestimate the true magnitude of disease. Among factors that may contribute to under-reporting are: delays in notification, limited collection or appropriate testing of specimens, health care seeking behavior among ill persons, limited resources and competing priorities in LHDs, and lack of reporting by clinicians and laboratories. Among factors that may contribute to changes in reporting are disease severity, the availability of new or less expensive diagnostic tests, changes in the case definition by CDC or CDPH, changes in mandatory reporting requirements, recent media or public attention, and active surveillance activities. Differential reporting practices among LHDs may also result in inconsistent reporting of patient information.

References

1. California Code of Regulations, Title 17, Sections 2500 and 2505 https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/ReportableDiseases.pdf

2. Center for Disease Control and Prevention, National Notifiable Diseases Surveillance System https://ndc.services.cdc.gov/

Note: As of 1/13/24, this dataset is no longer updated. This dataset reports daily on the number of people vaccinated by New York providers who have received a dose of the updated COVID-19 vaccine authorized on September 12, 2023. New York providers include hospitals, pharmacies, and other providers registered with the State to serve as points of distribution.

This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS). County-level vaccination data is based on data reported to NYSIIS by the providers administering vaccines. Residency is self-reported by the individual being vaccinated. This dataset includes limited data on vaccines administered through Federal entities (Veterans Health Administration) or performed outside of New York State to New York residents and will not be reflective of every dose administered to New York State residents in those settings. It does not include residents of New York City. NYSIIS data is used for county-level statistics.

These data represent a lower-bound estimate on updated COVID-19 vaccination totals. With the end of the COVID-19 public health emergency, COVID-19 vaccination records are no longer required to be submitted to NYSIIS for adults 19+. Reporting remains mandatory for children 18 and under.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

This study provides a macro-level societal and health system focused analysis of child vaccination rates in 30 European countries, exploring the effect of context on coverage. The importance of demography and health system attributes on health care delivery are recognized in other fields, but generally overlooked in vaccination. The analysis is based on correlating systematic data built up by the Models of Child Health Appraised (MOCHA) Project with data from international sources, so as to exploit a one-off opportunity to set the analysis within an overall integrated study of primary care services for children, and the learning opportunities of the ‘natural European laboratory’. The descriptive analysis shows an overall persistent variation of coverage across vaccines with no specific vaccination having a low rate in all the EU and EEA countries. However, contrasting with this, variation between total uptake per vaccine across Europe suggests that the challenge of low rates is related to country contexts of either policy, delivery, or public perceptions. Econometric analysis aiming to explore whether some population, policy and/or health system characteristics may influence vaccination uptake provides important results - GDP per capita and the level of the population’s higher education engagement are positively linked with higher vaccination coverage, whereas mandatory vaccination policy is related to lower uptake rates. The health system characteristics that have a significant positive effect are a cohesive management structure; a high nurse/doctor ratio; and use of practical care delivery reinforcements such as the home-based record and the presence of child components of e‑health strategies.

As of 2022, the BioNTech vaccine against the coronavirus (COVID-19) was administered the most in Germany. Figures were significantly higher for BioNTech vaccinations, compared to the other vaccines approved for use in the EU – Moderna, AstraZeneca and Janssen. BioNTech is a German biotechnological company, which developed a vaccine against COVID-19 in cooperation with U.S. pharmaceutical giant Pfizer.

New vaccines BioNTech and Moderna are mRNA vaccines, AstraZeneca is not, but all three have one thing in common – they have to be administered in two doses over a period of several weeks to provide protection against the virus. The Janssen vaccine, also referred to as Johnson & Johnson, referring to its manufacturer, requires one dose. Both BioNTech and Moderna vaccines have already been administered as booster shots while another coronavirus wave engulfs Germany. After initial shortages in deliveries at the beginning of Germany’s vaccination campaign at the end of December 2020, production has ramped up, also within the country, and the German government repeatedly assures the population that there are enough vaccines for first, second and booster shots.

The next wave Thus far there is no national vaccination mandate in Germany, though heated debate among political parties regarding the issue continues, particularly in the wake of rising coronavirus cases in the winter of 2021 and the emergence of the Omicron variant. While all the currently greenlighted vaccines against COVID-19 are not said to make the recipient immune to the virus, they are widely hailed as helping reduce the risk of a difficult illness or the possibility of a hospital stay.

Adult and Pediatric Vaccines Market Outlook

The global market size for adult and pediatric vaccines was valued at approximately $45 billion in 2023, and it is expected to grow significantly, reaching around $75 billion by 2032 with a CAGR of 6.2%. This substantial growth can be attributed to several key factors, including advancements in biotechnology, increased awareness about the importance of vaccinations, and ongoing efforts by governments and international organizations to improve immunization rates worldwide.

A primary growth factor in the adult and pediatric vaccines market is the increasing prevalence of infectious diseases. The rise of new pathogens, including the emergence of zoonotic diseases and the resurgence of previously controlled diseases, has necessitated a robust and dynamic approach to vaccination. Vaccines are crucial in preventing outbreaks and controlling the spread of infections, making them indispensable in public health strategies. Additionally, the COVID-19 pandemic has underscored the critical need for rapid vaccine development and deployment, significantly influencing the marketÂ’s trajectory.

Another significant growth driver is advancements in vaccine technology. Innovations such as mRNA vaccines, which have gained prominence due to their role in the COVID-19 pandemic, are paving the way for more efficient and faster vaccine development processes. These technological advancements are not only improving the efficacy and safety profiles of vaccines but also enabling the development of vaccines for a broader range of diseases. Furthermore, developments in cold chain logistics and vaccine delivery systems are enhancing the accessibility and distribution of vaccines, particularly in remote and underserved regions.

The growing awareness and advocacy for vaccination programs are also crucial contributors to market growth. Governments, non-governmental organizations (NGOs), and healthcare institutions are investing heavily in campaigns to educate the public about the benefits of vaccinations. These efforts are leading to higher immunization rates across various age groups, thereby reducing the incidence of vaccine-preventable diseases. Moreover, the implementation of mandatory vaccination policies in many countries is further bolstering market demand.

The role of Disease Control and Prevention Vaccine initiatives cannot be overstated in the context of global health security. These vaccines are essential tools in the fight against infectious diseases, providing a proactive approach to disease management and prevention. By immunizing populations, these vaccines help reduce the incidence and spread of diseases, ultimately saving lives and reducing healthcare costs. The efforts of organizations such as the Centers for Disease Control and Prevention (CDC) in promoting vaccine uptake and ensuring equitable access to vaccines are crucial in achieving high immunization coverage. These initiatives also support the development of new vaccines and the improvement of existing ones, ensuring that they are safe, effective, and accessible to all.

Regionally, North America currently dominates the adult and pediatric vaccines market, driven by high healthcare expenditure, advanced healthcare infrastructure, and significant government funding for vaccine research and development. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, propelled by increasing healthcare investments, improving immunization coverage, and a rising population base. Europe also holds a substantial share of the market due to strong government initiatives and a well-established healthcare system.

Vaccine Type Analysis

Live-attenuated vaccines are a critical segment of the adult and pediatric vaccines market. These vaccines use a weakened form of the virus or bacteria to elicit a strong and long-lasting immune response. They are particularly effective and have been used to combat diseases such as measles, mumps, rubella, and chickenpox. The efficacy of live-attenuated vaccines often requires fewer doses, making them cost-effective in large-scale immunization programs. However, they require stringent cold chain maintenance to remain effective, posing logistical challenges in regions with limited infrastructure.

Inactivated vaccines represent another significant segment. Unlike live-attenuated vaccines, inactivated vaccines use viruses or bacteria t

Travel Vaccines Market Outlook

The global travel vaccines market size was valued at approximately USD 3.5 billion in 2023, and it is forecasted to reach around USD 7.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% during the forecast period. The growth of this market is primarily driven by the increasing awareness among travelers about the risks of infectious diseases and the vital role of vaccines in preventing them.

One of the significant growth factors for the travel vaccines market is the rise in global travel and tourism. With international tourism crossing over 1.4 billion international arrivals in recent years, the need for preventive healthcare measures such as travel vaccines has become more pronounced. Travelers, especially those visiting developing countries, are at a higher risk of contracting diseases such as hepatitis, yellow fever, and typhoid. This has led to a growing emphasis on immunization, thereby propelling market growth.

Another key driver is the increasing number of government initiatives and recommendations for travel vaccinations. Various health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), advocate for specific vaccinations before traveling to certain regions. This regulatory support has significantly boosted the adoption of travel vaccines as a standard preventive measure, leading to increased market demand.

Technological advancements and innovations in vaccine development are also contributing to market expansion. The emergence of new vaccine formulations, improved vaccine delivery methods, and enhanced storage and transportation solutions have made travel vaccines more accessible and effective. The development of combination vaccines, which protect against multiple diseases, further simplifies the vaccination process, enhancing compliance among travelers.

The Tick-borne Encephalitis Vaccine is gaining attention as a critical component of travel health, especially for travelers heading to regions where tick-borne encephalitis (TBE) is prevalent. This vaccine is essential for those visiting rural or forested areas in parts of Europe and Asia, where the risk of TBE is higher. The disease, transmitted by tick bites, can lead to severe neurological complications, making vaccination a crucial preventive measure. As awareness of TBE increases, more travelers are seeking this vaccine to ensure their safety during outdoor activities such as hiking and camping. The inclusion of the Tick-borne Encephalitis Vaccine in travel health recommendations underscores its importance in comprehensive travel vaccine strategies.

From a regional perspective, the Asia Pacific region is expected to witness substantial growth in the travel vaccines market. This can be attributed to the rising middle-class population, increasing disposable incomes, and a surge in outbound travel from countries like China and India. Additionally, the prevalence of infectious diseases in some parts of the region necessitates the use of travel vaccines, thereby driving market growth. North America and Europe are also significant markets, supported by well-established healthcare infrastructures and high travel activity.

Vaccine Type Analysis

The travel vaccines market can be segmented by vaccine type, including Hepatitis A, Hepatitis B, Typhoid, Yellow Fever, Meningococcal, Rabies, Japanese Encephalitis, and Others. Hepatitis A vaccines are critical due to the high incidence of the disease in many parts of the world. With Hepatitis A being highly contagious and often spread through contaminated food and water, travelers to regions with poor sanitation are particularly advised to get vaccinated. Consequently, the demand for this vaccine type remains robust.

Hepatitis B vaccines are equally crucial as the disease poses significant health risks, including liver cirrhosis and cancer. The vaccine is particularly recommended for travelers who may engage in activities that increase the risk of exposure to bodily fluids. The rising awareness about the severity of hepatitis B and the availability of effective vaccines are propelling the growth of this segment.

Yellow Fever vaccines are mandatory for travel to certain parts of Africa and South America, where the disease is endemic. The strict travel regulations, combined with the potential severity of yellow fever, have led to a stead

Context

Overall US COVID-19 Vaccine administration and vaccine equity data at county level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Content

Date : Date data are reported on CDC COVID Data Tracker MMWR_week :MMWR Week Recip_County : County of residence Recip_State : Recipient State Series_Complete_Yes : Total number of people who are fully vaccinated (have second dose of a two-dose vaccine or one dose of a single-dose vaccine) based on the jurisdiction and county where recipient lives Series_Complete_12Plus : Total number of people 12+ who are fully vaccinated (have second dose of a two-dose vaccine or one dose of a single-dose vaccine) based on the jurisdiction where recipient lives Series_Complete_18Plus : Total number of people 18+ who are fully vaccinated (have second dose of a two-dose vaccine or one dose of a single-dose vaccine) based on the jurisdiction and county where recipient lives

happy learning….

Hope you like this dataset please don't forget to like this dataset

This dataset contains immunization status of kindergarten students in California in schools. Explanation of the different immunizations is in the attached data dictionary. The California Health and Safety Code Section 120325-75 requires students to provide proof of immunization for school and child care entry. Additionally, California Health and Safety Code Section 120375 and California Code of Regulation Section 6075 require all schools and child care facilities to assess and report annually the immunization status of their enrollees.

The annual kindergarten assessment is conducted each fall to monitor compliance with the California School Immunization law. Results from this assessment are used to measure immunization coverage among students entering kindergarten. Not all schools reported. This data set presents results from the kindergarten assessment and immunization coverage in kindergarten schools by county. To review individual school coverage and exemption rates in a separate lookup format, go to the School Lookup page at the Immunization Branch's Shots for School website: http://www.shotsforschool.org/lookup/

To see the PDF reports by year go to:https://www.shotsforschool.org/k-12/reporting-data/

See the attached file 'Notes on Methods' for data suppression in the '2016-17 ' data and after.

For earlier years of data: https://www.shotsforschool.org/k-12/reporting-data/

The Colorado Immunization Information System (CIIS) can estimate immunization uptake and track vaccination coverage levels over time. This data includes routine immunization rates calculated for 19-35 month old children and 13-17 year old adolescents in Colorado. To correct for active records in CIIS with out of date address information who likely no longer live in Colorado, 19-35 month olds are included in rate calculations if they have at least two non-COVID-19 and non-flu visits on record in CIIS before nine months of age. A visit is defined as a distinct date of immunization services. Adolescents are included in rate calculations if they have received at least one non-COVID-19 vaccine in the past five years. Routine immunization coverage rates are based solely on information available in CIIS. CIIS is a mandatory reporting system; vaccine providers are required by law to submit both immunization and exemption information to CIIS. Rate estimates are highly dependent on the completeness and accuracy of the data in CIIS. The widest variation in rates is typically seen in smaller counties, where fewer children and adolescents are included in rate calculations. Routine immunization rates calculated for 19-35 month old children include 1+ doses of MMR, 1+ Varicella, 3+ Hepatitis B, 3+ Hib, 3+ Polio, 4+ DTaP, 4+ PCV, and the seven-antigen series (4:3:1:3:3:1:4). Routine immunization rates calculated for 13-17 year old adolescents include 1+ doses of MenACWY, 1+ Tdap, up-to-date status for HPV overall, up-to-date status for HPV for males, and up-to-date status for HPV for females. Rates are provided at the state and county level. Rates are updated twice annually, and are available starting from the six month period spanning from July 1, 2015 through December 31, 2015. For each six month period, child or adolescent age is defined as of the beginning of the six month period. Immunizations administered and reported to CIIS as of the end of the six month period are included in rate calculations. Here is a brief description of the individual data fields (columns) included in this dataset: county: This field contains the geographic level of the corresponding rate. For state-level rates, ‘county’ is set to “COLORADO”. For county-level rates, ‘county’ corresponds to the Colorado county name (character). vaccine: This field contains the vaccine of the corresponding rate (character). percent: This field contains the percentage of children or adolescents who have received the corresponding number of doses of the vaccine in CIIS (numeric, three digits). starting_date: This field contains the beginning date of the six month time period (date, yyyy-mm-dd). time_period: This field contains a description of the six month time period (character). group: This field describes the age group of the corresponding rate (“19-35 month olds” or “13-17 year olds”) (character).publish_date: Data that this dataset was published to the CDPHE Open Data Portal.

Vaccinations Solutions for Pets Market Outlook

The global market size for vaccination solutions for pets was projected to be approximately USD 5.5 billion in 2023 and is forecasted to reach USD 9.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. The growth of this market can be attributed to increasing pet ownership, heightened awareness about pet health, and advances in veterinary medicine.

One of the primary growth factors driving the vaccination solutions for pets market is the increasing pet humanization trend. As pets are increasingly being considered as family members, owners are more willing to invest in their health and well-being. This shift in perception has led to a higher expenditure on pet healthcare services, including vaccinations. Furthermore, the rising incidences of zoonotic diseases have emphasized the importance of regular vaccinations, thereby driving market growth.

Another significant factor contributing to market expansion is the advancements in veterinary medicine and biotechnology. Innovations such as DNA vaccines and recombinant vaccines are proving to be more effective and safer, leading to higher adoption rates. These advancements not only enhance the efficacy of vaccines but also reduce the potential side effects, making them more acceptable to pet owners and veterinarians alike.

There is also a growing awareness about preventive healthcare among pet owners, influenced by various veterinary campaigns and government initiatives. Many countries have implemented mandatory vaccination programs for pets to curb the spread of infectious diseases. Additionally, the rise of social media and online platforms has made information about pet health more accessible, encouraging pet owners to adhere to vaccination schedules. These factors collectively are propelling the market forward.

Geographically, North America and Europe currently dominate the market due to the high pet ownership rates, well-established veterinary infrastructure, and significant investments in pet healthcare. However, the Asia Pacific region is expected to witness the highest growth rate, driven by increasing disposable incomes, urbanization, and a burgeoning middle class that is more inclined towards pet adoption and healthcare. The growing availability of veterinary services and products in emerging economies further supports this regional growth trend.

Product Type Analysis

The market for vaccination solutions for pets can be segmented into core vaccines and non-core vaccines. Core vaccines are those that are universally recommended for all pets, regardless of their geographical location or lifestyle. These include vaccines for rabies, distemper, parvovirus, and adenovirus. The demand for core vaccines remains consistently high due to their critical role in preventing life-threatening diseases. These vaccines are often mandated by law, further ensuring their widespread adoption.

Non-core vaccines, on the other hand, are administered based on the pet's risk of exposure to certain diseases. These include vaccines for Lyme disease, Bordetella, and feline leukemia virus (FeLV). The market for non-core vaccines is also growing, driven by the increasing awareness among pet owners about the specific health risks their pets may face. Veterinarians play a crucial role in guiding pet owners about the necessity of these vaccines based on the pet’s lifestyle and environment.

Advancements in vaccine technology are significantly impacting both core and non-core vaccine markets. The development of combination vaccines, which protect against multiple diseases in a single shot, is gaining popularity. These combination vaccines offer the dual benefits of reducing the number of injections a pet needs and ensuring comprehensive protection, thus increasing compliance with vaccination schedules.

The growing trend of personalized pet healthcare is also influencing the product type segment. Veterinarians are increasingly adopting tailored vaccination plans that take into account the individual pet’s health status, age, and lifestyle. This personalized approach is particularly relevant for non-core vaccines and is expected to drive market growth in this segment.

Report Scope

According to Cognitive Market Research, the global Yellow Fever Vaccine market size will be USD 4528.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1811.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1358.55 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1041.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 226.43 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 90.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
The Sylvatic Yellow Fever category is the fastest-growing segment of the Yellow Fever Vaccine industry

Market Dynamics of Yellow Fever Vaccine Market

Key Drivers for Yellow Fever Vaccine Market

Rising Incidence of Yellow Fever to Boost Market Growth

Yellow fever is a potentially fatal viral disease spread by infected mosquitoes. According to the World Health Organization (WHO), as of 2023, 34 countries in Africa and 13 in Central and South America are either endemic or have endemic regions for yellow fever. Between August 26 and November 29, 2022, 22 additional confirmed cases were reported across ten countries. However, after a retrospective review, only seven new confirmed cases and one death were identified. Since 2021, in the WHO African Region, a total of 203 confirmed cases and 252 probable cases of yellow fever have been reported, with 40 deaths, resulting in a case fatality rate (CFR) of 9%. Among the confirmed cases, 23 deaths were recorded, reflecting a CFR of 11%. The high CFR among confirmed cases remained consistent, with 17 deaths (11%) in 2021 and six deaths (12%) in 2022. This increasing disease burden is driving significant demand for yellow fever vaccines, especially in endemic areas. Recent severe outbreaks in Brazil, Angola, and the Democratic Republic of Congo have intensified global awareness and the need for preventive measures, further stimulating the vaccine market.

Expansion of Vaccination Programs to Drive Market Growth

In 2017, the WHO, in collaboration with UNICEF and Gavi, the Vaccine Alliance, launched the EYE Strategy to protect at-risk populations in 40 countries across Africa and the Americas through mass vaccination campaigns and by ensuring a sustainable vaccine supply. Since the start of the current outbreak (2021 to December 7, 2022), a total of 4,385,320 people have been vaccinated in five countries—Cameroon, the Central African Republic, Chad, Ghana, and Kenya—through the ICG-supported response. A reactive campaign in Kembe Satema, Central African Republic, from November 2 to 19, 2022, achieved 101.7% coverage, while a campaign in Bambari, which ended on November 23, 2022, reached 87.7% coverage based on preliminary results. These efforts have accelerated vaccine deployment and expanded immunization programs, providing growth opportunities for vaccine manufacturers. Additionally, many countries in yellow fever-endemic regions have incorporated the vaccine into their national immunization schedules, ensuring steady demand. In several African and South American nations, yellow fever vaccination is mandatory for children, further boosting the market.

Restraint Factor for the Yellow Fever Vaccine Market

Vaccine Supply Shortages and High-Cost Will Limit Market Growth

Yellow fever vaccine production is concentrated among a limited number of manufacturers, leading to supply bottlenecks. This has caused periodic shortages, especially during large-scale outbreaks when demand surges. The production of the live-attenuated vaccine is complex, relying on chicken embryos for cultivation, which limits the ability to rapidly scale up production. In sudden outbreaks, vaccine demand often exceeds supply. The global stockpile maintained by the World Health Organization (WHO) is sometimes insufficient t...

Diphtheria, Tetanus, and Pertussis Combined Vaccine Market Outlook

The global market size for Diphtheria, Tetanus, and Pertussis (DTP) combined vaccines is projected to grow significantly from $4.5 billion in 2023 to approximately $7.8 billion by 2032, with a compound annual growth rate (CAGR) of 6.3%. The primary growth factors driving this market include rising awareness about the importance of immunization, government initiatives to eradicate infectious diseases, and the increasing prevalence of infectious diseases worldwide. Furthermore, the introduction of new vaccines and advancements in vaccine technology are expected to bolster market growth over the forecast period.

The growing awareness regarding the benefits of vaccination has played a crucial role in driving the demand for DTP combined vaccines. Governments and non-governmental organizations (NGOs) worldwide are actively involved in promoting immunization programs to prevent outbreaks of these potentially fatal diseases. Public health campaigns and educational initiatives have effectively conveyed the importance of vaccination, leading to higher vaccination rates and, consequently, increased market demand. Additionally, global health organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to emphasize the significance of vaccinations, further solidifying the necessity of DTP combined vaccines.

Technological advancements in vaccine development have also contributed significantly to the market's growth. Innovations such as conjugate vaccines, which offer enhanced immunogenicity and longer-lasting immunity, are gaining traction. Research and development efforts are continually focused on improving vaccine formulations to increase efficacy and reduce side effects, making them safer and more effective for various age groups. These advancements not only enhance the overall efficiency of immunization programs but also foster market growth by expanding the range of available vaccines and their applications.

Government initiatives and healthcare policies play a pivotal role in the market's expansion. Many countries have implemented mandatory vaccination programs for children and special populations, ensuring widespread immunization coverage. Subsidized or free vaccination programs, funded by governments or international health organizations, make vaccines accessible to economically disadvantaged populations. Additionally, efforts to integrate vaccination services into primary healthcare systems have streamlined vaccine delivery, thereby boosting vaccination rates and market growth.

Vaccine Type Analysis

The Diphtheria, Tetanus, and Pertussis combined vaccine market is segmented by vaccine type into DTaP, Tdap, and Td. The DTaP vaccine, primarily administered to infants and young children, holds the largest market share due to its widespread use in national immunization programs. DTaP vaccines are designed to provide immunity against all three diseases in a single shot, making them highly convenient for parents and healthcare providers. The robust adoption of DTaP in pediatric vaccination schedules drives its dominant position in the market. Moreover, continuous updates to immunization guidelines that include DTaP as a core vaccine further bolster its market presence.

Tdap vaccines, recommended for adolescents and adults, are gaining significant traction. These vaccines serve as boosters to renew immunity that may have waned since childhood immunization. With an increasing focus on adult and adolescent immunization to control disease outbreaks and protect vulnerable populations, the demand for Tdap vaccines is on the rise. Additionally, Tdap vaccination during pregnancy has been shown to protect newborns from pertussis, adding a critical dimension to its market growth. The inclusion of Tdap in school entry and workplace vaccination requirements further propels its demand.

The Td vaccine segment, which does not include the pertussis component, is primarily used for booster doses in adults to maintain immunity against tetanus and diphtheria. Although it occupies a smaller market share compared to DTaP and Tdap, its importance cannot be overlooked. Td vaccines are particularly crucial in areas with high incidences of tetanus, such as regions with limited access to healthcare and in populations with lower vaccine coverage. Efforts to improve adult immunization rates, especially in developing countries, contribute to the steady demand for Td vaccines.

Overall, the continued emphasis on comprehensive im

Series Name: (S.4.C.13) Extent to which countries have laws and regulations that guarantee full and equal access to women and men aged 15 years and older to sexual and reproductive health care information and education: Component 13: HPV Vaccine (percent)Series Code: SH_LGR_ACSRHEC13Release Version: 2020.Q2.G.03 This dataset is the part of the Global SDG Indicator Database compiled through the UN System in preparation for the Secretary-General's annual report on Progress towards the Sustainable Development Goals.Indicator 5.6.2: Number of countries with laws and regulations that guarantee full and equal access to women and men aged 15 years and older to sexual and reproductive health care, information and educationTarget 5.6: Ensure universal access to sexual and reproductive health and reproductive rights as agreed in accordance with the Programme of Action of the International Conference on Population and Development and the Beijing Platform for Action and the outcome documents of their review conferencesGoal 5: Achieve gender equality and empower all women and girlsFor more information on the compilation methodology of this dataset, see https://unstats.un.org/sdgs/metadata/

BackgroundAccording to a recent paper by Gelfand et al., COVID-19 infection and case mortality rates are closely connected to the strength of social norms: “Tighter” cultures that abide by strict social norms are more successful in combating the pandemic than “looser” cultures that are more permissive. However, countries with similar levels of cultural tightness exhibit big differences in mortality rates. We are investigating potential explanations for this fact. Using data from Germany and Japan—two “tight” countries with very different infection and mortality rates—we examined how differences in socio-demographic and other determinants explain differences in individual preventive attitudes and behaviors.MethodsWe compared preventive attitudes and behaviors in 2020 based on real-time representative survey data and used logit regression models to study how individual attitudes and behaviors are shaped by four sets of covariates: individual socio-demographics, health, personality, and regional-level controls. Employing Blinder-Oaxaca regression techniques, we quantified the extent to which differences in averages of the covariates between Japan and Germany explain the differences in the observed preventive attitudes and behaviors.ResultsIn Germany and Japan, similar proportions of the population supported mandatory vaccination, avoided travel, and avoided people with symptoms of a cold. In Germany, however, a significantly higher proportion washed their hands frequently and avoided crowds, physical contact, public transport, peak-hour shopping, and contact with the elderly. In Japan, a significantly higher proportion were willing to be vaccinated. We also show that attitudes and behaviors varied significantly more with covariates in Germany than in Japan. Differences in averages of the covariates contribute little to explaining the observed differences in preventive attitudes and behaviors between the two countries.ConclusionConsistent with tightness-looseness theory, the populations of Japan and Germany responded similarly to the pandemic. The observed differences in infection and fatality rates therefore cannot be explained by differences in behavior. The major difference in attitudes is the willingness to be vaccinated, which was much higher in Japan. Furthermore, the Japanese population behaved more uniformly across social groups than the German population. This difference in the degree of homogeneity has important implications for the effectiveness of policy measures during the pandemic.